ATE150299T1 - Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker - Google Patents

Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker

Info

Publication number
ATE150299T1
ATE150299T1 AT90302365T AT90302365T ATE150299T1 AT E150299 T1 ATE150299 T1 AT E150299T1 AT 90302365 T AT90302365 T AT 90302365T AT 90302365 T AT90302365 T AT 90302365T AT E150299 T1 ATE150299 T1 AT E150299T1
Authority
AT
Austria
Prior art keywords
tetrahydro
inflammation
phenyl
treatment
derivatives
Prior art date
Application number
AT90302365T
Other languages
English (en)
Inventor
Kenneth B Koe
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE150299(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE150299T1 publication Critical patent/ATE150299T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90302365T 1989-03-07 1990-03-06 Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker ATE150299T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Publications (1)

Publication Number Publication Date
ATE150299T1 true ATE150299T1 (de) 1997-04-15

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90302365T ATE150299T1 (de) 1989-03-07 1990-03-06 Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker

Country Status (17)

Country Link
US (2) US4981870A (de)
EP (1) EP0386997B1 (de)
JP (2) JPH0714870B2 (de)
KR (1) KR920005810B1 (de)
AT (1) ATE150299T1 (de)
AU (1) AU610036B2 (de)
CA (1) CA2011428C (de)
DE (1) DE69030212T2 (de)
DK (1) DK0386997T3 (de)
HU (1) HU221624B1 (de)
IE (1) IE81047B1 (de)
IL (1) IL93576A (de)
MY (1) MY106272A (de)
NZ (1) NZ232800A (de)
PH (1) PH26542A (de)
PT (1) PT93351B (de)
ZA (1) ZA901743B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
ID23503A (id) 1997-07-01 2000-04-27 Pfizer Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
NZ538741A (en) * 2002-09-16 2007-01-26 Sepracor Inc Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
US20040087661A1 (en) * 2002-09-16 2004-05-06 Sepracor, Inc. Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
CN101553217A (zh) * 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CA2636324C (en) * 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CN101484210A (zh) * 2006-05-31 2009-07-15 塞普拉科公司 用反-4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗疼痛病
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
KR20090111322A (ko) * 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2427178B1 (de) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermale freisetzungszusammensetzung mit wirkstoff-calciumphosphat-partikelkomplexen und anwendungsverfahren
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2919788A4 (de) 2012-11-14 2016-05-25 Univ Johns Hopkins Verfahren und zusammensetzungen zur behandlung von schizophrenie
EP3827820A1 (de) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam zur verbesserung der kognitiven funktion
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
CA2948829A1 (en) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
US10076503B2 (en) * 2014-05-13 2018-09-18 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of ADHD
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
ZA901743B (en) 1991-10-30
DE69030212T2 (de) 1997-06-26
JP3020808B2 (ja) 2000-03-15
US4981870A (en) 1991-01-01
DK0386997T3 (da) 1997-04-14
IE900798L (en) 1990-09-07
JPH0714870B2 (ja) 1995-02-22
CA2011428A1 (en) 1990-09-07
IL93576A (en) 1995-12-08
EP0386997A2 (de) 1990-09-12
AU5079690A (en) 1990-09-20
HUT59000A (en) 1992-04-28
DE69030212D1 (de) 1997-04-24
US5061728A (en) 1991-10-29
HU901325D0 (en) 1990-05-28
EP0386997B1 (de) 1997-03-19
IE81047B1 (en) 1999-12-01
PH26542A (en) 1992-08-19
PT93351A (pt) 1990-11-07
AU610036B2 (en) 1991-05-09
KR920005810B1 (ko) 1992-07-20
MY106272A (en) 1995-04-29
PT93351B (pt) 1996-03-29
IL93576A0 (en) 1990-11-29
KR900013949A (ko) 1990-10-22
JPH07173056A (ja) 1995-07-11
NZ232800A (en) 1997-07-27
HU221624B1 (hu) 2002-12-28
JPH02300121A (ja) 1990-12-12
CA2011428C (en) 1994-11-08
EP0386997A3 (de) 1992-04-29

Similar Documents

Publication Publication Date Title
ATE150299T1 (de) Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69333062D1 (de) 4-mercaptoacetylamino-[2]benzazepinon(3)- derivate, und verwendung als enkephalinase-inhibitoren
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
BR9300707A (pt) Composicao para o tratamento dos cabelos e processo de condicionamento dos cabelos
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
FR2491334B1 (de)
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE69033413D1 (de) Mittel zur Behandlung von Metalloberflächen
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE3679781D1 (de) Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
DE69006508D1 (de) Azeotropähnliche zusammensetzungen von 1,3-dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.
IL89901A0 (en) Strobilurine derivatives
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69226171D1 (de) Zusammensetzung und verwendung von substituierten 1,3-dithiolo- und 1,4-dithiino-chinoxalinen als antimikrobielle mittel
DE69117566D1 (de) Verwendung von Isomonoolen zur Behandlung und Prophylaxe von Krebserkrankungen
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee